RO112580B1 - Metoda pentru profilaxia si/sau tratamentul bolii asociate cu un nivel nedorit al factorului de necrozare tumorala (tnf) - Google Patents

Metoda pentru profilaxia si/sau tratamentul bolii asociate cu un nivel nedorit al factorului de necrozare tumorala (tnf) Download PDF

Info

Publication number
RO112580B1
RO112580B1 RO95-00041A RO9500041A RO112580B1 RO 112580 B1 RO112580 B1 RO 112580B1 RO 9500041 A RO9500041 A RO 9500041A RO 112580 B1 RO112580 B1 RO 112580B1
Authority
RO
Romania
Prior art keywords
lysozyme
tnf
disease
dimer
treatment
Prior art date
Application number
RO95-00041A
Other languages
English (en)
Romanian (ro)
Inventor
Witold Kiczka
Original Assignee
Nika Health Products Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nika Health Products Ltd filed Critical Nika Health Products Ltd
Publication of RO112580B1 publication Critical patent/RO112580B1/ro

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2462—Lysozyme (3.2.1.17)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Materials Engineering (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RO95-00041A 1992-07-13 1993-07-13 Metoda pentru profilaxia si/sau tratamentul bolii asociate cu un nivel nedorit al factorului de necrozare tumorala (tnf) RO112580B1 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PL92295273A PL173978B1 (pl) 1992-07-13 1992-07-13 Sposób oddziaływania na wydzielanie cytokin w hodowli limfocytów krwi obwodowej
PCT/EP1993/001841 WO1994001127A1 (en) 1992-07-13 1993-07-13 Lysozyme dimer and compositions containing the same

Publications (1)

Publication Number Publication Date
RO112580B1 true RO112580B1 (ro) 1997-11-28

Family

ID=20058087

Family Applications (1)

Application Number Title Priority Date Filing Date
RO95-00041A RO112580B1 (ro) 1992-07-13 1993-07-13 Metoda pentru profilaxia si/sau tratamentul bolii asociate cu un nivel nedorit al factorului de necrozare tumorala (tnf)

Country Status (31)

Country Link
US (1) US6132715A (enExample)
EP (1) EP0651654B1 (enExample)
JP (1) JPH07508744A (enExample)
KR (1) KR100289841B1 (enExample)
CN (1) CN1057937C (enExample)
AT (1) ATE252392T1 (enExample)
AU (1) AU677786B2 (enExample)
BG (1) BG63331B1 (enExample)
BR (1) BR9306722A (enExample)
CA (1) CA2140140A1 (enExample)
CZ (1) CZ286725B6 (enExample)
DE (2) DE69333258T2 (enExample)
DK (1) DK0651654T3 (enExample)
ES (1) ES2074037T3 (enExample)
FI (1) FI950144A0 (enExample)
GE (1) GEP20012466B (enExample)
GR (1) GR950300039T1 (enExample)
HU (1) HU218151B (enExample)
MX (1) MX9304197A (enExample)
NZ (2) NZ254135A (enExample)
OA (1) OA10125A (enExample)
PL (1) PL173978B1 (enExample)
PT (1) PT651654E (enExample)
RO (1) RO112580B1 (enExample)
RU (1) RU2145875C1 (enExample)
SG (1) SG52727A1 (enExample)
SK (1) SK282377B6 (enExample)
TW (1) TW259710B (enExample)
UA (1) UA49789C2 (enExample)
WO (1) WO1994001127A1 (enExample)
ZA (1) ZA935046B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6183742B1 (en) 1992-07-13 2001-02-06 Nika Health Products, Limited Applications of lysozyme dimer
DZ1964A1 (fr) * 1995-01-13 2002-10-15 Nika Health Products Ltd Nouvelle applications d'un dimère de lysozyme.
AU5884096A (en) * 1995-05-30 1996-12-18 Lectin Biopharma, Inc. Method of using lectins for agglutination and collection of menstrual flow
US6123937A (en) * 1997-03-14 2000-09-26 Nika Health Products, Limited Applications of lysozyme dimer
ITMI981148A1 (it) 1998-05-22 1999-11-22 Therapicon Srl Utilizzo di lisozima c modificato per preparare composizioni medicinali per il trattamento di alcune gravi malattie
EP1174147A1 (en) * 2000-06-27 2002-01-23 Nika Health Products Limited Reversal of antibiotic resistance with lysozyme dimer
US20050244402A1 (en) * 2004-04-30 2005-11-03 Villanueva Julie M Absorption of pain-causing agents
RU2320367C1 (ru) * 2006-08-22 2008-03-27 Государственное образовательное учреждение дополнительного профессионального образования Российская медицинская академия последипломного образования Федерального агентства по здравоохранению и социальному развитию (ГОУ ДПО РМАПО Росздрава) Способ сопроводительного лечения острого лимфобластного лейкоза
RU2351351C1 (ru) * 2007-08-08 2009-04-10 Тихоокеанский Институт Биоорганической Химии Дальневосточного Отделения Российской Академии Наук (Тибох Дво Ран) Средство, повышающее неспецифическую сопротивляемость организма к бактериальным эндотоксинам
RU2472467C2 (ru) * 2011-04-13 2013-01-20 Государственное научное учреждение Краснодарский научно-исследовательский ветеринарный институт (ГНУ КНИВИ) Способ профилактики и лечения гастроэнтеритов, обусловленных бактериозами, у телят
CN105106626A (zh) * 2015-09-30 2015-12-02 成都倍加特生物科技有限公司 一种治疗月经期感染的汤剂药物及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR4020M (enExample) * 1965-01-29 1966-03-21
FR2215201A1 (en) * 1973-01-24 1974-08-23 Theranol Lab Broad-spectrum antibiotic compsns. - contg. antibiotic resistant lactic bacilli and enzyme diffusing-agent
JPS5533408A (en) * 1978-08-30 1980-03-08 Eisai Co Ltd Immunity-increasing agent
JPS5533409A (en) * 1978-08-30 1980-03-08 Eisai Co Ltd Carcinostatic agent
JPS5543040A (en) * 1978-09-25 1980-03-26 Eisai Co Ltd Immunity raising agent
US4221794A (en) * 1979-06-21 1980-09-09 Newport Pharmaceuticals International, Inc. Method of imparting immunomodulating and antiviral activity
US4457919A (en) * 1980-03-14 1984-07-03 Newport Pharmaceutical International, Inc. Method of imparting immunomodulating, antiviral or antitumor activity
US4510144A (en) * 1981-08-26 1985-04-09 Newport Pharmaceuticals International Methods of imparting immunomodulating activity with dihydrothiazolo purine derivatives
US4739046A (en) * 1985-08-19 1988-04-19 Luzio Nicholas R Di Soluble phosphorylated glucan
US4744984A (en) * 1985-10-08 1988-05-17 Vetrepharm Research, Inc. Antiviral immunotherapeutic agent and preparation thereof
DE3782958D1 (de) * 1986-02-19 1993-01-21 Imreg Inc Verfahren und mittel zum pruefen eines immunsystems.
WO1989011294A1 (en) * 1988-05-26 1989-11-30 Nika Health Care, Inc. Antiviral or antibacterial compound and method of use
DE3817955A1 (de) * 1988-05-27 1989-11-30 Hoechst Ag Tnf-inhibitor enthaltendes arzneimittel
JP2568447B2 (ja) * 1988-05-31 1997-01-08 ナップ・システムズ・（ユーエスエイ）・インコーポレーテッド 印刷原板を処理するための装置及び方法
WO1991000092A1 (en) * 1989-06-13 1991-01-10 Smithkline Beecham Corporation Inhibition of interleukin-1 and tumor necrosis factor production by monocytes and/or macrophages
US5314816A (en) * 1990-01-08 1994-05-24 Nika Health Products Ltd. Method of preparing lysozyme dimers
MC2243A1 (fr) * 1990-01-08 1993-02-23 Nika Health Products Ltd Procede de preparation de dimeres de la ribonuclease
CA2088352A1 (en) * 1990-08-03 1992-02-04 Klaus M. Esser Tnf inhibitors

Also Published As

Publication number Publication date
DK0651654T3 (da) 2004-02-23
FI950144A7 (fi) 1995-01-12
ES2074037T3 (es) 2004-07-01
SK4095A3 (en) 1995-09-13
KR100289841B1 (ko) 2001-05-15
DE69333258T2 (de) 2004-08-26
ES2074037T1 (es) 1995-09-01
US6132715A (en) 2000-10-17
PL295273A1 (en) 1994-01-24
RU2145875C1 (ru) 2000-02-27
OA10125A (en) 1996-12-18
HUT70973A (en) 1995-11-28
SK282377B6 (sk) 2002-01-07
PT651654E (pt) 2004-03-31
TW259710B (enExample) 1995-10-11
KR950702432A (ko) 1995-07-29
JPH07508744A (ja) 1995-09-28
NZ299377A (en) 2001-02-23
CA2140140A1 (en) 1994-01-20
DE651654T1 (de) 1996-01-04
ATE252392T1 (de) 2003-11-15
FI950144L (fi) 1995-01-12
PL173978B1 (pl) 1998-05-29
CN1087278A (zh) 1994-06-01
DE69333258D1 (de) 2003-11-27
CZ8595A3 (en) 1995-09-13
HU9500098D0 (en) 1995-03-28
WO1994001127A1 (en) 1994-01-20
BR9306722A (pt) 1998-12-08
MX9304197A (es) 1994-02-28
UA49789C2 (uk) 2002-10-15
GEP20012466B (en) 2001-06-25
AU677786B2 (en) 1997-05-08
SG52727A1 (en) 1998-09-28
ZA935046B (en) 1994-02-07
HU218151B (hu) 2000-06-28
GR950300039T1 (en) 1995-07-31
BG63331B1 (bg) 2001-10-31
EP0651654B1 (en) 2003-10-22
EP0651654A1 (en) 1995-05-10
NZ254135A (en) 1996-11-26
BG99287A (bg) 1995-08-28
CN1057937C (zh) 2000-11-01
CZ286725B6 (en) 2000-06-14
FI950144A0 (fi) 1995-01-12
AU4568693A (en) 1994-01-31

Similar Documents

Publication Publication Date Title
Khan et al. Effect of clarithromycin and azithromycin on production of cytokines by human monocytes
Sordillo et al. Controlling acute Escherichia coli mastitis during the periparturient period with recombinant bovine interferon gamma
EP0380484A1 (en) Use of a lysozyme dimer and / or ribonuclease dimer for the production of an antiviral or antibacterial medicament.
Sordillo et al. Modulation of bovine mammary neutrophil function during the periparturient period following in vitro exposure to recombinant bovine interferon gamma
RO112580B1 (ro) Metoda pentru profilaxia si/sau tratamentul bolii asociate cu un nivel nedorit al factorului de necrozare tumorala (tnf)
Kemper et al. Immunomodulatory treatment of Mycobacterium avium complex bacteremia in patients with AIDS by use of recombinant granulocyte-macrophage colony-stimulating factor
JP2004501056A (ja) 抗微生物ヒストンｈ１組成物、キット及びその使用方法
AU641698B2 (en) Method for the prevention and treatment of bovine mastitis
US5234684A (en) Method for the prevention and treatment of bovine mastitis
US5336488A (en) Method of treating or preventing mastitis in animals with involuting mammary glands by administering recombinant cytokines
US5342612A (en) Compositions for the treatment of mammalian diseases
US20190314460A1 (en) Ovotransferrin treatment for the reproductive tract
US6593457B1 (en) Lymphocyte-derived antimicrobial protein (LDAP) and methods of isolating and producing and using the protein
PL176407B1 (pl) Kompozycja farmaceutyczna zawierająca dimer lizozymu
Maoleekoonpairoj et al. Lack of protection against bacterial infections in patients with advanced cancer treated by biologic response modifiers
CA2288982A1 (en) Methods for preventing and treating the insult-induced metabolic imbalance in humans and other animals
Holland et al. The cutaneous propionibacteria